Concurrent Acquired Hemophilia A and Lupus Anticoagulant Managed With Emicizumab and Immunosuppression: A Case Report

Read full text Summarise with VIRAT
Authors: Julie Williamson, Kristi Johnson Smock, Karen Moser, Richard A. King
Cited by: 0
References: 20

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Acquired hemophilia A (AHA) is a rare bleeding disorder that can be accompanied by challenges in diagnosis and management when there is a concurrent lupus anticoagulant. A 72‐year‐old male with no bleeding or thrombotic history presented with new spontaneous hematomas of the extremities and an isolated severely prolonged aPTT. Collaboration between hematology and coagulation laboratory specialists resulted in timely diagnosis and optimized assay interpretation in the setting of concomitant AHA and a previously unknown lupus anticoagulant. Emicizumab was beneficial in the successful treatment of AHA in the presence of a lupus anticoagulant. Concurrent AHA and lupus anticoagulant cases are rare and present diagnostic and management challenges that can be optimized with interdisciplinary collaboration.

Fields of Study & Subjects

Hemophilia Treatment and Research Systemic Lupus Erythematosus Research Platelet Disorders and Treatments

Publication details

Journal / source
Case Reports in Hematology
Volume
2026
Issue
1
Pages
4158470
Publication date
1 January 2026
Language
EN